Overview

Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Diphosphonates
Zoledronic Acid